A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Clinical trial NCT04236310 · UNKNOWN
Trial details
- NCT number
- NCT04236310
- Sponsor
- Ruijin Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-15
- Primary completion
- 2022-12-31
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.